This is a phase 1, single-center, dose selection study to evaluate the efficacy, safety, and
pharmacokinetics of ThisCART19A (allogeneic CAR-T targeting CD19) in patients with Auto-CAR T
relapsed B-cell non-Hodgkin's lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University